Furthermore, microtubule localization was not just from alternate kinesin 3 family 'K-loop' binding, as KIF1C loop 6/10 mutant 350 with further mutations in the K-loop (NRSK or GTKT) were still able to localize to microtubules.
We therefore concluded that selection for clonal populations with stable ectopic XIAP expression is either impossible or could yield mutants with a further deregulated cell cycle.
The combination of the best mutations led to a double mutant with an even further improved functional expression, a higher activity in dimerization of ferulic acid, and a much better decolorization efficiency than the single mutants and wild-type.
For both samples, the decrease of the percent proportion of mutant colonies gradually continued with further increasing the concentration; however, the antimutagenic efficiency was much higher for the BBI alkaloids sample, for which the bleaching percentage (corresponding to the AO 2.3 μM curve) reaches ~5% level for the highest concentration tested.
To provide further support for the role of interference we have added analysis of I3bc crossovers in a zip4 (interference defective) single mutant with varying heterozygosity, which further supports a role for crossover interference in these phenomena.
The complete conversion of HPA and propanal to (3S -1,3-dihydroxypentan-2-one with a mutant transketolase further demonstrated the applicability of the microfluidic system for organic synthesis.
As expected, we found that prior treatment with the Chk1 inhibitor results in inhibition of BAK multimerization with the Y108A mutant further in line with the findings that Chk1 activity is not required for the initial step of BAK activation.
Interestingly, Tsc2−/− MEFs reconstituted with the TSC2-5A mutant were further reduced in their capacity to differentiate into adipocytes (Figure 5D) and accumulated lower levels of intracellular triglycerides than the cells expressing wild-type TSC2 (Figure 5E).
More recently, mutations in DNMT3A, but not NPM1, were identified in pre-leukaemic HSCs from patients with double DNMT3A/NPM1 mutant AML, further supporting the leukaemia-initiating pedigree of mutant DNMT3A (Shlush et al., 2014).
